Brought to you by 
Enzon, SkyePharma sign two drug delivery deals
17 Jun 2014
Executive Summary
Enzon (life-threatening diseases) has signed two deals with SkyePharma. The first involves developing as many as three products to be administered via oral, injected, or topical means. The second gives Enzon North American rights to SkyePharma's FDA-approved DepoCyt (cytarabine), a sustained-release injectable chemotherapeutic for lymphomatous meningitis.
Deal Industry
- Biotechnology
- Pharmaceuticals
-
Pharmaceuticals
-
Drug Delivery
- Controlled Release
- Topical Delivery
-
Drug Delivery
Deal Status
- Final
Deal Type
-
Alliance
- Includes Royalty or Profit Split Information
- Intra-Biotech Deal
- R&D and Marketing (Licensing)
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Enzon, SkyePharma sign two drug delivery deals
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice